Ipamorelin: The Complete Guide to the Selective GH Secretagogue

Ipamorelin: The Complete Guide to the Selective GH Secretagogue

Key Takeaways:

• Ipamorelin is a synthetic pentapeptide that stimulates GH release via the ghrelin/GHS-R1a receptor pathway.
• It is considered "selective" because it triggers GH release without significantly increasing cortisol, prolactin, or ACTH, unlike older GHRPs.
• Animal and early human research confirms GH pulse amplification. Large-scale human trials are limited.
• Ipamorelin is not FDA-approved for any indication. All use outside of research settings is off-label.
• It is almost always stacked with a GHRH analog like CJC-1295 to maximize GH output through dual-pathway stimulation.

Important: This is not medical advice. Ipamorelin is a research peptide, not an FDA-approved medication. The content below summarizes available scientific literature for educational purposes only. Consult a qualified healthcare provider before using any peptide compound. See our full medical disclaimer.

---

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide, meaning it is a chain of five amino acids. It was developed in the 1990s by Novo Nordisk as part of research into growth hormone secretagogues, and it quickly distinguished itself from earlier compounds in the same class.

Ipamorelin belongs to the growth hormone releasing peptide (GHRP) family. These peptides stimulate the pituitary gland to produce and release growth hormone. What made ipamorelin notable was not just that it worked, but that it worked cleanly. Earlier GHRPs like GHRP-2 and GHRP-6 stimulated GH release but also triggered meaningful increases in cortisol and prolactin. Ipamorelin does not, at least not at standard doses. This selectivity made it an attractive candidate for further study.

For context on the broader category this compound belongs to, see our growth hormone secretagogues overview.

How ipamorelin works: the mechanism

Ipamorelin binds to the growth hormone secretagogue receptor 1a (GHS-R1a), commonly called the ghrelin receptor. This is the same receptor pathway activated by ghrelin, the hunger hormone produced in the stomach.

When ipamorelin binds to GHS-R1a on pituitary somatotroph cells, it triggers a calcium signaling cascade that causes the cell to release stored growth hormone in a pulsatile burst. This mimics the natural GH pulses the body produces, especially during deep sleep and exercise.

Two properties make ipamorelin useful as a research compound:

Selectivity. Standard GHRP compounds activate multiple receptor pathways. Ipamorelin is highly selective for GHS-R1a. Research published in Growth Hormone and IGF Research (PMID: 9849822) confirmed that ipamorelin did not significantly increase ACTH, cortisol, or prolactin in rat studies at doses that produced robust GH release, distinguishing it sharply from GHRP-6 and hexarelin.

Pulse fidelity. Ipamorelin produces a clean, discrete GH pulse. It does not produce the prolonged, blunted GH release seen with some other secretagogues. This is considered favorable because it more closely resembles natural GH physiology.

What the research shows

The published research on ipamorelin is primarily preclinical. The foundational studies come from animal models, predominantly rats, with some primate data. Key findings include:

GH release and IGF-1 elevation

A 1998 study examining ipamorelin's selectivity profile (PMID: 9849822) confirmed dose-dependent GH release in rats, with GH pulses significantly above baseline after subcutaneous administration. The compound showed consistent activity across multiple dosing intervals without evidence of desensitization in the short term.

Research comparing GHRPs also reported that ipamorelin produced IGF-1 elevation downstream of GH stimulation, consistent with expected physiology. Elevated IGF-1 mediates many of the downstream effects attributed to GH secretagogue use, including changes in muscle protein synthesis and fat metabolism.

Body composition effects in animal models

GH and IGF-1 together influence body composition through two primary pathways. GH directly promotes lipolysis, the breakdown of stored fat for energy. IGF-1 supports protein synthesis and lean tissue maintenance. Animal studies examining GH secretagogue use generally show reductions in fat mass and maintenance or mild increases in lean mass under conditions of adequate nutrition.

A study examining ipamorelin in postmenopausal osteoporosis models (PMID: 28586565) found that GH secretagogue treatment including ipamorelin-class peptides produced measurable changes in lean body mass and bone mineral density markers in animal subjects, suggesting effects beyond simple GH elevation.

Gut motility research

One area where ipamorelin has a unique published evidence base is gastrointestinal motility. A study (PMID: 9849822) and related research found that ipamorelin could enhance postoperative gut motility in animal models. This led to brief interest in it as a potential treatment for postoperative ileus (slowed bowel motility after surgery), though this research pathway was not developed into an approved drug.

Community-reported dosing protocols

The following reflects commonly reported self-administration protocols in online communities and harm reduction contexts. This is not medical guidance.

Typical dose range: 100-300 mcg per injection, subcutaneous

Frequency: 1-3 times daily, with common targets being:

• Once daily, approximately 30-60 minutes before sleep (to coincide with natural nighttime GH pulse)
• Twice daily, before sleep and before morning exercise
• Three times daily for maximum GH output, though benefit over twice-daily protocols is debated

Administration route: Subcutaneous injection into abdominal fat or thigh

Cycle length: Community reports suggest 8-12 week cycles followed by a break period. The rationale is to prevent downregulation of GHS-R1a receptors over time, though human data on receptor desensitization with ipamorelin specifically is limited.

Stacking: Ipamorelin is almost universally stacked with CJC-1295 in community practice. The rationale is dual-pathway stimulation. CJC-1295 works via the GHRH receptor, ipamorelin works via the ghrelin receptor. Both pathways stimulate GH release, and activating them simultaneously produces a GH pulse that is significantly larger than either compound alone. For a detailed look at this combination, see our CJC-1295 + ipamorelin stack guide.

Timing relative to meals: Most protocols recommend administering ipamorelin in a fasted state or at least 2 hours after a meal. Elevated insulin from meals can blunt GH release. Administering in a low-insulin environment is thought to maximize the GH pulse.

Reported benefits (based on community experience and extrapolated research)

It is important to be precise here. The following benefits are reported by users or extrapolated from GH physiology research. Direct human clinical trials proving these outcomes with ipamorelin specifically are limited.

Improved body composition. The most commonly reported outcome. Users describe gradual fat reduction, particularly from central/visceral depots, alongside maintenance or mild increase in lean mass. This is consistent with what GH elevation would be expected to produce based on established GH physiology.

Enhanced sleep quality. Many users report deeper, more restorative sleep. This aligns with the relationship between GH and slow-wave sleep. The largest natural GH pulses occur during deep sleep, and amplifying those pulses appears to improve sleep quality subjectively.

Recovery improvements. Some users report faster recovery from training or injury. GH and IGF-1 both support tissue repair processes, which provides a plausible mechanism.

Skin and connective tissue changes. Some users report improvements in skin texture and joint comfort, consistent with collagen synthesis effects of IGF-1.

Reduced visceral fat over time. This is extrapolated from the tesamorelin literature (the only FDA-approved GH peptide for body composition) and from general GH research, not from ipamorelin-specific trials.

Side effects and risks

Ipamorelin's selectivity profile gives it a cleaner side effect picture than older GHRPs, but it is not without potential issues.

Water retention. GH stimulation increases extracellular fluid retention. This is common and typically resolves if dosing is reduced or discontinued.

Tingling or numbness. Peripheral tingling, particularly in hands, is reported. This is associated with GH-driven fluid shifts and is consistent with side effects seen in therapeutic GH use.

Headaches. Some users report mild headaches, particularly in the early weeks of use.

Hunger stimulation. Ipamorelin works via the ghrelin receptor, and ghrelin is the primary hunger hormone. However, ipamorelin's hunger effects are considered mild compared to GHRP-6, which is notorious for strong appetite stimulation. Many ipamorelin users report minimal to no hunger increase.

Cortisol and prolactin. At standard doses, ipamorelin does not meaningfully elevate these hormones, which is its key differentiator from older GHRPs.

IGF-1 elevation risks. Chronically elevated IGF-1 is associated in some epidemiological literature with increased cancer risk, particularly for certain hormonally sensitive cancers. This is a long-term risk consideration that applies to all GH secretagogues. The evidence is associative, not causal, but it warrants caution.

Unknown long-term safety profile. Large-scale, long-duration human trials do not exist for ipamorelin. Long-term safety data simply is not available.

Ipamorelin vs other GH secretagogues

vs GHRP-2: GHRP-2 produces a stronger GH pulse than ipamorelin but also causes more cortisol and prolactin elevation. For users prioritizing clean GH release without stress hormone effects, ipamorelin is generally preferred. See our GHRP-2 vs GHRP-6 comparison for related context.

vs GHRP-6: GHRP-6 causes significant appetite stimulation, which some users want and others do not. Ipamorelin has much weaker hunger effects. GH output from GHRP-6 is somewhat higher, but the side effect trade-off shifts preferences toward ipamorelin for most users.

vs sermorelin: Sermorelin is a GHRH analog (different receptor pathway) rather than a GHRP. It produces more natural, gentle GH stimulation but a smaller peak pulse than ipamorelin. The two can be stacked by mechanism, similar to the CJC-1295 approach.

vs CJC-1295: These are complementary rather than competing. CJC-1295 is a GHRH analog, ipamorelin is a GHRP. Stacking them produces significantly larger GH release than either compound alone, which is why the combination is the most common GH peptide protocol in community use.

What ipamorelin will not do

Setting realistic expectations matters.

Ipamorelin will not produce GLP-1-class weight loss. It does not suppress appetite meaningfully, it does not slow gastric emptying, and it does not reduce caloric intake directly. Users who approach ipamorelin expecting semaglutide-like results will be disappointed. For a comparison of these categories, see our GH secretagogues vs HGH guide.

Body composition changes from ipamorelin are gradual. The research and community experience consistently point to slow, cumulative changes over months, not dramatic before-and-after transformations in weeks.

Results are also highly context-dependent. Sleep, nutrition, training, and stress management all interact with GH output. Ipamorelin amplifies GH pulses, but it does not replace the other variables that determine body composition outcomes.

FAQ

Is ipamorelin FDA-approved? No. Ipamorelin is not FDA-approved for any indication. It is classified as a research compound and is not legal for human use in the United States outside of a clinical research context.

How long does ipamorelin take to work? Community reports suggest early effects like improved sleep quality can appear within 1-2 weeks. Body composition changes are typically reported after 6-12 weeks of consistent use.

Can women use ipamorelin? Women have used ipamorelin in community and some research contexts. The selectivity profile and lack of androgenic activity make it theoretically lower risk than anabolic hormones for women. However, the standard caveats about limited human trial data apply equally regardless of sex.

Does ipamorelin cause water retention? Some water retention from GH stimulation is common, particularly in the first few weeks. It typically stabilizes. Reducing the dose usually reduces water retention.

Is ipamorelin safe to stack with CJC-1295? The CJC-1295 and ipamorelin combination is the most commonly used GH peptide stack. The mechanisms are complementary and the combination does not introduce additional unique risks beyond those of each compound individually. That said, stacking increases total GH output, which also amplifies potential side effects.

---

Sources

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
2. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981487
3. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343
4. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998. PMID: 9467542
5. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28586565

---

This content is for educational purposes only and does not constitute medical advice. Ipamorelin is not FDA-approved for human use. Consult a licensed healthcare provider before using any research compound. Full disclaimer.